EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Generalizability in real‐world trials

Anatol-Fiete Näher iD, Marvin Kopka iD, Felix Balzer iD, Matthias Schulte-Althoff iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Anatol-Fiete Näher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Digital Global Public Health, Hasso Plattner Institute for Digital Engineering, University of Potsdam, Potsdam, Germany. Hauptthemen laut MEDLINE: Research Design, Data Mining. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Real‐world evidence (RWE) trials have a key advantage over conventional randomized controlled trials (RCTs) due to their potentially better generalizability. High generalizability of study results facilitates new biological insights and enables targeted therapeutic strategies. Random sampling of RWE trial participants is regarded as the gold standard for generalizability. Additionally, the use of sample correction procedures can increase the generalizability of trial results, even when using nonrandomly sampled real‐world data (RWD). This study presents descriptive evidence on the extent to which the design of currently planned or already conducted RWE trials takes sampling into account. It also examines whether random sampling or procedures for correcting nonrandom samples are considered. Based on text mining of publicly available metadata provided during registrations of RWE trials on clinicaltrials.gov, EU‐PAS, and the OSF‐RWE registry, it is shown that the share of RWE trial registrations with information on sampling increased from 65.27% in 2002 to 97.43% in 2022, with a corresponding increase from 14.79% to 28.30% for trials with random samples. For RWE trials with nonrandom samples, there is an increase from 0.00% to 0.95% of trials in which sample correction procedures are used. We conclude that the potential benefits of RWD in terms of generalizing trial results are not yet being fully realized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignData MiningHumansRandomized Controlled Trials as TopicRegistriesClinical Trials as TopicPragmatic Clinical Trials as TopicMetadata

Autor:innen und Institutionen

  • Digital Global Public Health, Hasso Plattner Institute for Digital Engineering, University of Potsdam, Potsdam, Germany.
  • Institute of Medical Informatics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Institute of Psychology and Ergonomics (IPA), Division of Ergonomics, Technische Universität Berlin, Berlin, Germany.
  • Department of Information Systems, Freie Universität Berlin, Berlin, Germany.

ORCID-Profile: Anatol-Fiete Näher, Marvin Kopka, Felix Balzer, Matthias Schulte-Althoff

Zitieren

APA

Näher, A. F., Kopka, M., Balzer, F., & Schulte-Althoff, M. (2024). Generalizability in real‐world trials. Clinical and Translational Science. https://doi.org/10.1111/cts.13886

Vancouver

Näher AF, Kopka M, Balzer F, Schulte-Althoff M. Generalizability in real‐world trials. Clinical and Translational Science. 2024. doi:10.1111/cts.13886

BibTeX
@article{Nher2024,
  author = {Näher, Anatol-Fiete and Kopka, Marvin and Balzer, Felix and Schulte-Althoff, Matthias},
  title = {Generalizability in real‐world trials},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13886}
}
Kostenlos starten →